Two Sigma Investments’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRV
Two Sigma Investments's ACRV Position: Q3 2026 in Review
Two Sigma Investments reduced its Acrivon Therapeutics (ACRV) stake by 12% in Q3 2026, selling an estimated $146K and leaving 564,956 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3480.
Two Sigma Investments first reported a position in ACRV in Q4 2022 and has held it in 7 quarters since. The position peaked at $1.41M in Q4 2025. 47 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.
- Two Sigma Investments held 564,956 shares of Acrivon Therapeutics worth $1.16M as of Q3 2026.
- Two Sigma Investments sold 76,542 Acrivon Therapeutics shares in Q3 2026, an estimated $146K.
- Acrivon Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #3480 holding.
- Two Sigma Investments first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 7 quarters since.
- Two Sigma Investments's Acrivon Therapeutics position peaked at $1.41M in Q4 2025.
- 47 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.
Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.